Navigation Links
Catalent Signs Commercial Manufacturing Agreement with US WorldMeds for Lofexidine
Date:9/5/2017

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

US WorldMeds has the rights to commercialize lofexidine in the U.S., which is currently approved as Britlofex™ in the United Kingdom. Catalent and US WorldMeds have worked together to successfully tech transfer the manufacturing from a facility overseas to Catalent’s Winchester, Kentucky, facility, where they have produced registration batches to support US WorldMeds’ New Drug Application to the Food and Drug Administration (FDA) and the anticipated commercial launch.

Lofexidine received Fast Track designation by the FDA, a process designed to expedite the review of drugs that treat serious conditions and address an unmet medical need. If approved, lofexidine would be the first non-narcotic and non-addictive medication in the United States for treatment of symptoms associated with opioid withdrawal.

“Symptoms of opioid withdrawal can be a significant barrier in seeking help and breaking the cycle of dependence and addiction. We are excited to join forces with US WorldMeds to bring a potential new treatment option to a major health issue spanning the nation.”

Catalent’s Winchester, facility has more than 20 years’ experience in product development, technology transfer and commercial manufacturing. The site has produced over three billion tablets and capsules annually and launched more than 100 new products into the market since its inception.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated more than $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at http://www.prweb.com/releases/2017/09/prweb14660080.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Catalent Provides Commercial Manufacturing of Lexicon Pharmaceuticals' Orphan Drug XERMELO™ Following FDA Approval
2. Catalent to Launch Innovative Fish Oil Supplement Product at Vitafoods Europe
3. Challenges and Strategies to Automate Potency Assays to be Discussed by Catalent Expert at Upcoming CASSS Bioassays Symposium
4. Catalent Expands Kansas City Clinical Storage and Secondary Packaging Capabilities to Meet Growing Demand for Cold Chain Services
5. Catalent Wins Prestigious Clinical Supply Chain Excellence Award at BioPharma Asia Convention
6. Challenges and Innovation in Clinical Trial Supply to be Presented by Catalent Experts at Upcoming Conferences
7. Catalent to Host Workshop with Leading Biologics Experts on Advanced Protein Development and Delivery at Upcoming Drug Delivery Partnerships Conference
8. Innovative Strategies for the Development of Lipid-based Oral Medicines to be Presented by Catalent and Gattefossé at Forthcoming Workshop
9. Accelerated Biopharmaceutical Development through Strategic Analytical Partnerships to be Discussed by Catalent Expert at Upcoming WCBP Conference
10. Catalent to Develop Softgel Capsules for JOT’s Leading Orphan Disease Candidates
11. Catalent Biologics Collaborates with PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... Want to ... 1, Cerebral Palsy Alliance Research Foundation (CPARF) is thrilled to launch its fourth annual ... research. A fully virtual challenge, STEPtember meets everyone wherever they are at this moment ...
(Date:8/31/2020)... Colo. (PRWEB) , ... August 31, 2020 , ... ... provider of innovative higher-learning opportunities through high-quality, career-relevant, and affordable online education – ... Responder Psychology . , Among the first of its kind in the ...
(Date:8/31/2020)... ... 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put financial strain on ... ways to trim the fat from our monthly expenses and put more into savings, if ... that you have a financial safety net in place in case something were to happen ...
(Date:8/31/2020)... CHICAGO (PRWEB) , ... August 31, 2020 , ... In ... Chicago West Loop is donating 10 percent of each hotel room booked with ... House Charities® of Chicagoland & Northwest Indiana (RMHC-CNI) , effective immediately. Donations will ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... intended to improve outcomes for patients with advanced heart failure, today announced that ... grant in the amount of $555,358 from the National Heart, Lung, and Blood ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... Fla. (PRWEB) , ... August 27, 2020 , ... Bridge ... of Directors. Dr. Friedman is an adult and pediatric neuro-oncologist who serves on the ... and as an educator at Duke University Medical School. , Internationally recognized, Dr. Friedman ...
(Date:8/26/2020)... SAN DIEGO (PRWEB) , ... August 26, 2020 , ... ... the 2020 Infection Control Company of the Year by MedTech Outlook. , ... Operating Officer. “For the first time, clinicians who wear gloves on their hands, goggles ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... entered into definitive agreement to acquire ProCE, a nationally recognized provider of ... technicians. , CEA represents a growing alliance of CME/CE and service ...
Breaking Medicine Technology: